Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
Kidney Cancer
Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC
Biomarkers Identify Immune Checkpoint Inhibitor-Related Acute Kidney Injury
Prompt diagnosis of AKI and the ability to rule out immune checkpoint inhibitors as the cause may allow patients to continue with cancer immunotherapy.
Opdivo Plus Cabometyx Approved for Advanced Kidney Cancer
The approval was based on data from the randomized, open-label phase 3 CheckMate-9ER.
